RxDoctor Payments Data

John Jacoby, MD

General Practice · New Rochelle, NYNPI 1790853778

Payments from drug & device makers

$2,837in general payments, 2019–2025

Across 99 payments — averaging $28.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$599
  • GSK$570
  • AbbVie$382
  • Boehringer Ingelheim$261
  • Genentech USA, Inc.$169
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$155
  • plus $700 from 14 others

What the payments were for

  • Food & beverage$2,70295%
  • Education$1345%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,837 in reported general payments places this provider in the 90th percentile of 5,764 general practice providers in New York.

See all general practice providers in New York

Medicare billing

Part B allowed, 2024
$66,863
Medicare patients
109
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$40,938
VraylarCariprazine Hcl19$27,416
XareltoRivaroxaban28$24,306
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$22,542
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen29$16,939
TrintellixVortioxetine Hydrobromide22$14,461
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,854
JanuviaSitagliptin Phosphate11$9,208
Breo ElliptaFluticasone/Vilanterol21$8,183
Diclofenac Sodium24$4,114
Oxycodone Hcl70$2,679
Colesevelam Hcl14$1,874
Albuterol Sulfate HfaAlbuterol Sulfate44$1,234
Simvastatin111$941
Ventolin HfaAlbuterol Sulfate11$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$382$27,41619 claims
Johnson & JohnsonXarelto$21$24,30628 claims
AstraZenecaBreztri Aerosphere$599$22,54232 claims
GSKTrelegy Ellipta, Breo Ellipta$570$20,03740 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$49$14,46122 claims
MerckJanuvia$15$9,20811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,764 general practice providers in New York.

Other general practice in New Rochelle

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →